Akorn Stock Analysis, Valuation (NASDAQ:AKRX)

Add to My Stocks
$18.52 $0.08 (0.43%) AKRX stock closing price Mar 22, 2018 (Closing)
Watch Robo Advisor Video of AKRX Stock Analysis
Updated on : Mar 22, 2018
previous close
AKRX 18.5 (0%)
S&P 500 2643.7 (0%)
Closing Price On: Mar 22, 2018
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Generic Drugs
Sector :
5 Quarter Revenue
Revenue Growth
Compared to the industry
Long Term Growth
5 Year CAGR:
Operating Profit
Operating Margin:
Sector Average:
5 Quarter Net Profit
Net Margins
LTM Margin
Debt/Equity Ratio
Debt/Equity Ratio:
Compared to the industry
Cash Flow
Operating cash flow:
Net Income:
FCF Margin
Recent Growth
Long Term Growth
Operating Margins
Net Margins
High Debt Burden
Rating: ★★★★★★★★★★ (0/5)
Other Metrics
Return on Invested Capital:
Return on Equity:
Free Cash Flow Margin:
Double Tap To Exit Full Screen

Akorn Stock Analysis

57 5 2

Investors can watch the Amigobulls Akorn stock analysis video here. Our AKRX analysis video highlights revenue and profit trends along with other important metrics such as valuation to find what makes the stock attractive.

Note: Amigobulls stock rating is our opinion based on the historical performance of the company's fundamentals. It is not indicative of the future performance of the stock.

Akorn, Inc. Stock Rating 2.9/5

We at Amigobulls use various financial measures including profit margins, revenue growth and dividends for AKRX stock analysis. We compare Akorn valuation with its sector peers to gauge relative attractiveness of AKRX stock. Based on a company's historical fundamentals we arrive at Akorn stock rating which is indicative of the company's financial performance.

Should you buy AKRX stock?

  • The company has a good Free Cash Flow (FCF) margin of 11.7%.

Should you sell AKRX stock?

  • Akorn revenue saw a decline of -34.4% YoY in 2017 Q4.
  • Long term revenue growth of 26.8% over the past 5 years has been disappointing.
  • Akorn reported an average operating margin of -2.1% over the Last Twelve Months (LTM).
  • Akorn posted an average Net loss of -2.9% in the last twelve months.
  • With a debt/equity ratio of  0.98, Akorn is highly leveraged in comparison to Medical peers.
  • Akorn's negative ROIC of -0.5% indicates operational inefficiency.
  • A negative ROE of -2.9% indicates that the company is not able to generate profits with the money shareholders have invested.

Comments on this video and Akorn stock

Amigobulls Akorn stock analysis helps in evaluating the financial statements of a company to arrive at a conclusion about the fair value of AKRX stock. Company's fundamentals remain one of the key driver of AKRX stock and helps investors in making good buy and sell decision.

While doing a study of the company financials, Akorn revenue growth and profit or net income are two main metrics which help in identifying whether AKRX stock is overvalued or undervalued. Technical analysis comes in handy to check whether the market sentiment is in line with the fundamental picture of the company.